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The impact of the COVID-19 pandemic on cancer deaths 
due to delays in diagnosis in England, UK: a national, 
population-based, modelling study
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Summary
Background Since a national lockdown was introduced across the UK in March, 2020, in response to the COVID-19 
pandemic, cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic 
cases prioritised for diagnostic intervention. In this study, we estimated the impact of delays in diagnosis on cancer 
survival outcomes in four major tumour types.
Methods In this national population-based modelling study, we used linked English National Health Service (NHS) 
cancer registration and hospital administrative datasets for patients aged 15–84 years, diagnosed with breast, 
colorectal, and oesophageal cancer between Jan 1, 2010, and Dec 31, 2010, with follow-up data until Dec 31, 2014, and 
diagnosed with lung cancer between Jan 1, 2012, and Dec 31, 2012, with follow-up data until Dec 31, 2015. We use a 
routes-to-diagnosis framework to estimate the impact of diagnostic delays over a 12-month period from the 
commencement of physical distancing measures, on March 16, 2020, up to 1, 3, and 5 years after diagnosis. To model 
the subsequent impact of diagnostic delays on survival, we reallocated patients who were on screening and routine 
referral pathways to urgent and emergency pathways that are associated with more advanced stage of disease at 
diagnosis. We considered three reallocation scenarios representing the best to worst case scenarios and reflect actual 
changes in the diagnostic pathway being seen in the NHS, as of March 16, 2020, and estimated the impact on net 
survival at 1, 3, and 5 years after diagnosis to calculate the additional deaths that can be attributed to cancer, and the 
total years of life lost (YLLs) compared with pre-pandemic data.
Findings We collected data for 32 583 patients with breast cancer, 24 975 with colorectal cancer, 6744 with oesophageal 
cancer, and 29 305 with lung cancer. Across the three different scenarios, compared with pre-pandemic figures, we 
estimate a 7·9–9·6% increase in the number of deaths due to breast cancer up to year 5 after diagnosis, corresponding 
to between 281 (95% CI 266–295) and 344 (329–358) additional deaths. For colorectal cancer, we estimate 1445 
(1392–1591) to 1563 (1534–1592) additional deaths, a 15·3–16·6% increase; for lung cancer, 1235 (1220–1254) to 1372 
(1343–1401) additional deaths, a 4·8–5·3% increase; and for oesophageal cancer, 330 (324–335) to 342 (336–348) 
additional deaths, 5·8–6·0% increase up to 5 years after diagnosis. For these four tumour types, these data correspond 
with 3291–3621 additional deaths across the scenarios within 5 years. The total additional YLLs across these cancers 
is estimated to be 59 204–63 229 years.
Interpretation Substantial increases in the number of avoidable cancer deaths in England are to be expected as a result 
of diagnostic delays due to the COVID-19 pandemic in the UK. Urgent policy interventions are necessary, particularly 
the need to manage the backlog within routine diagnostic services to mitigate the expected impact of the COVID-19 
pandemic on patients with cancer.
Funding UK Research and Innovation Economic and Social Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 
4.0 license.
Introduction
A national lockdown was introduced across the UK on 
March 23, 2020, as part of the national strategy to flatten 
the curve of the COVID-19 pandemic and reduce the 
potential impact on the UK National Health Service 
(NHS).1 The lockdown has been associated with a 
decrease in, or cessation of, most non-COVID-19 NHS 
services, and increasing concern about the effect on other 
patient groups requiring time-critical access to health-
care services. These patient groups include patients with 
cancer for whom timely diagnosis and the prompt 
initiation of treatment is vital for ensuring optimal 
outcomes.2,3
Since the beginning of the pandemic, multiple changes 
in the provision of cancer care from the point of diagnosis, 
including modification of treatment schedules (change 
in therapy, deferral, or omission), have been advised by 
professional bodies and commissioners of services 
globally.4–7 However, substantial heterogeneity has been 
seen in the imple mentation of these recommendations 
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across providers nationally and internationally and for 
individual patients. Such variations in the extent of 
treatment delay, and in changes to treatment doses and 
schedules (including new treat ment techniques) mean 
that modelling of these variations in practice on cancer 
outcomes at a population level is challenging.
Instead, in this study, we focused on analysing the 
impact of changes in cancer diagnostic pathways and 
subsequent delays in diagnosis during the COVID-19 
pandemic. Routine non-urgent diagnostic work initiated 
by referral from both primary care (general practitioners 
[GPs]) and secondary care teams (eg, for radiology or 
endoscopic procedures8) has been deferred across 
the UK. Cancer screening services have been suspended, 
and patients’ only routes to diagnosis since lockdown 
began have been via urgent 2-week-wait referral pathways 
for suspected cancer initiated by the GP or through direct 
presentation to an emergency department.9 Patients are 
eligible for these rapid access 2-week-wait pathways to 
access diagnostic investigations, on the basis of their age, 
symptom profile (eg, dysphagia), signs (eg, breast lump), 
or results of investigations (eg, iron deficiency anaemia) 
as specified by guidelines developed by the National 
Institute for Health and Care Excellence.9
However, since March, 2020, changes in health-seeking 
behaviour have been observed, with urgent 2-week-wait 
cancer referrals decreasing by up to 80% in response to 
physical distancing and concerns about contracting 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2).10 Additionally, some form of physical 
distancing is expected to continue for up to 12 months, 
which will probably further affect presentations to health-
care services.11,12
Quantifying the impact of delays in diagnosis on stage 
and prognosis is complex, but a routes-to-diagnosis 
approach provides a validated methodological framework 
for understanding their effect. Work by Elliss-Brookes 
and colleagues13 showed that referral routes to diagnosis 
are characterised by differences in both stage at 
presentation and survival. For example, urgent 2-week-
wait referrals for suspected cancer and emergency 
presentations are asso ciated with later stage of disease at 
diagnosis than diag noses via routine GP and secondary 
care referral routes and screening. Additionally, diagnosis 
after initial presen tation to an emergency department is 
consistently asso ciated with the worst survival outcomes 
compared with all other routes.13
Given the changes in health-seeking behaviour and 
availability and access to diagnostic services as a result 
of the COVID-19 lockdown, these routes to diagnosis 
provide a framework for estimating the impact of these 
changes on stage migration and excess cancer mortality 
on the basis of patients moving to different referral 
routes during the pandemic.
The effect of delayed presentation on patients with 
cancer is not immediate, and premature death as a result 
Research in context
Evidence before this study
In the UK, national COVID-19 pandemic measures since 
March 16, 2020, have resulted in the suspension of cancer 
screening and deferral of routine diagnostic investigations. 
Additionally, urgent 2-week wait referrals for patients with 
suspected cancer initiated by general practitioners (GPs) have 
decreased by up to 80% in response to physical distancing. 
To identify studies reporting on the current or predicted impact of 
diagnostic delay on cancer mortality during the COVID-19 
pandemic, we searched PubMed for articles in English published 
between Jan 1 and April 30, 2020, to identify national estimates 
and methods of estimation using the search terms (“COVID-19” 
OR “coronavirus” OR “SARS-CoV-2”) AND “cancer” AND 
(“diagnosis” OR “diagnostic”) AND “delay”. To date, no study has 
attempted to model the impact of changes in health-seeking 
behaviour and in the availability of and access to diagnostic 
services in the UK as a result of the COVID-19 lockdown on cancer 
survival and the additional number of deaths expected.
Added value of this study
To our knowledge, this study is the first of its kind to estimate 
the impact of delays in diagnostic pathways due to pandemic 
lockdown measures on cancer survival for four major tumour 
types. We use linked national cancer registration and hospital 
datasets, which provide a robust template for understanding the 
impact of current and predicted changes in availability, access, 
and health-seeking behaviour in response to the COVID-19 
pandemic on cancer survival. We used a routes-to-diagnosis 
framework, which is novel and provides a transparent approach 
to understanding what components of the diagnostic pathway 
need to be targeted as part of health service mitigation and 
recovery programmes. Additionally, this method does not 
require any new estimation of changes in cancer outcomes, but 
derives this from previous real-world observations. We also 
estimated the years of life lost to understand the wider welfare 
effects resulting from avoidable cancer deaths, and how this 
varies according to tumour type and the age profile of men and 
women diagnosed with these cancers. 
Implications of all the available evidence
Our results are conservative estimates of the number of 
additional deaths and years of life lost because we do not 
consider the effect of suboptimal or delayed cancer treatment. 
These data are essential for policy makers to drive changes in 
national lockdown and stay-at-home messaging, and to 
urgently reduce diagnostic delays, particularly for routine 
investigations, through outreach and accessibility programmes. 
Our model can also be used by other countries in their unique 
health-care settings to understand the impact of delays in 
diagnosis on cancer outcomes.
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might occur up to 5 years later and will differ according to 
tumour type. In this study, using national population 
datasets of patients diagnosed and treated in the English 
NHS, we estimated the impact of delays in diagnosis that 
are attributed to the lockdown measures put in place in 
the UK in March, 2020, for four major tumour types: 
breast, colorectal, lung, and oesophageal. We chose these 
tumour types because they differ in their predominant 
routes to referral (including screening), stage at presen-
tation, and both short-term and long-term prognoses 
according to stage. We estimated the effect on patient 
survival and the number of additional deaths expected due 
to these cancers, and the additional years of life lost (YLLs).
Methods
Study design and population
In this national, population-based, modelling study, we 
obtained information on adults in England, UK, with 
non-small-cell lung cancer (hereafter referred to as lung 
cancer: International Classification of Diseases 
10th edition C33, C34), cancers of the colon (C18) and 
rectum (C19), cancers of the oesophagus and gastro-
oesophageal junction (C15, C16.0), and women with 
breast cancer (C50) from the National Cancer Registration 
Service. The pre-pandemic cohort refers to patients 
diagnosed between Jan 1, 2010, and Dec 31, 2010, 
with follow-up data until Dec 31, 2014, for cancers of the 
colon, rectum, oesophagus, and breast, and to patients 
diagnosed between Jan 1, 2012, and Dec 31, 2012, with 
follow-up data until Dec 31, 2015, for lung cancer. We 
restricted the analyses to patients aged 15–84 years at 
diagnosis and those who had a known route of diagnosis 
coded (ie, 91% of patients for colorectal cancer, 93% of 
patients for oesophageal cancer, 94% of patients for 
breast cancer, and 97% of patients for lung cancer).
The National Cancer Registration Service records and 
updates patient and tumour characteristics for almost all 
cancers diagnosed in England (98–100%).14 We derived 
infor mation on referral pathways from linkages of the 
cancer registrations with secondary care data (Hospital 
Episode Statistics), screening records, and data on cancer 
waiting times.13 We did these linkages using deter-
ministic linkage methods using each individual patient’s 
NHS Number, with a linkage success of 99–100%.14 We 
derived information on patient’s comorbidity status from 
Hospital Episode Statistics diagnostic codes when 
patients attend hospital.15 We determined levels of 
deprivation via the quintiles of the Index of Multiple 
Deprivation income domain for the patients’ residential 
postcodes, measured at Lower Super Output Area level.16 
We used this information to link each patient with their 
expected mortality according to age, sex, deprivation, and 
region of residence using general population life tables.
This study was done in accordance with existing 
statutory and ethical approvals from the Confidentiality 
Advisory Group and Research Ethics Committee 
(PIAG 1–05(c)/2007 and REC 13/LO/0610).
Conceptual framework
We assumed that the incidence of each of the four tumour 
types of interest will remain relatively stable year on year 
on the basis of trends in previous years (2010–18),17 and 
that the ongoing COVID-19 pandemic and UK lockdown 
will mean patients are more likely to delay presentation. 
We estimated the subsequent impact on survival by 
reallocating patients from screening and non-urgent 
routine referral pathways (from GPs and secondary care) 
to urgent pathways—namely, 2-week wait referral routes 
and presentation at an emergency department. Both of 
these urgent pathways are associated with later stage 
of diagnosis and enabled us to estimate the impact of 
diagnostic delay on stage migration and survival outcome.
We justified our reallocation model on four assumed 
factors. First, 2-week-wait and emergency pathways are 
the only referral routes at the present time. Second, 
although routine diagnostic work and non-urgent referral 
pathways are delayed and screening suspended, some 
patients awaiting investigation will become symptomatic 
as their cancer progresses and will meet the criteria for 
urgent 2-week wait referral for suspected cancer or 
present as emergencies direct to secondary care. Third, 
for patients awaiting routine diagnostic investigations 
from their GP and secondary care referrals, substantial 
delays are expected (>6 months)12 due to the backlogs of 
routine work across all medical and surgical services 
increasing the likelihood of disease progression, which we 
estimated via reallocation to 2-week wait and emergency 
pathways. Finally, changes in health-seeking behaviour as 
a result of the pandemic means that some patients will 
delay presentation until more prominent symptoms 
develop, and these patients will be more likely to present 
through 2-week-wait and emergency pathways.
The starting point for our estimation is from 
March 16, 2020, which is the date physical distancing 
measures were introduced in the UK, and the impact is 
modelled over a 12-month period to account for the 
expected duration of disruption to services and patterns 
of referral. This period defines our cohort of expected 
number of cancer diagnoses for each tumour type, but 
we acknowledge that patients might present and be 
diagnosed beyond this period because of diagnostic 
delay. Our model reallocates patients on the basis of 
pre-pandemic ratios. For example, if 10% of new diag-
noses for a given tumour type are after an emergency 
department presentation, and 90% are via an outpatient 
referral, our simulation analysis will maintain these 
proportions when reallocating patients from screening 
and routine referral pathways.
For patients with breast cancer diagnosed via the 
screening referral pathway, we accounted for the fact that 
many are diagnosed with pre-invasive disease18 or disease 
that is unlikely to progress even within a 12-month 
period. Therefore, we reallocated only 25% of patients 
diagnosed with breast cancer through the NHS breast 
cancer screening programme. This percentage reflects 
For more on the Hospital 
Episode Statistics database see 
http://content.digital.nhs.uk/hes
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the proportion of patients who are diagnosed with breast 
cancer through screening referral pathways with 
tumours at stage III–IV, node-positive, or metastatic 
disease at the time of diagnosis. 
We used reallocation to estimate the excess mortality 
compared with the pre-pandemic period. For colorectal 
cancer, we undertook reallocation separately for colon 
and rectal cancer because the proportion of patients 
presenting via the different referral routes differed 
between the two cancers, as did the cancer stage at the 
time of diagnosis.
Scenarios
We based our analysis on three sets of predictions 
according to possible changes in referral patterns 
(figure 1) representing the best and worst case scenarios. 
For scenario A, we estimated survival outcomes for 
patients by reallocating those who are expected to be 
diagnosed through screening and routine referral 
pathways (GP or secondary care) to 2-week-wait and 
emergency presentation pathways, from March 16, 2020. 
Scenario B is the same as scenario A, but from March 16, 
we simulated the effect of an 80% reduction in 2-week-
wait referrals, which has already been observed during 
the lockdown period,10 and assumed that this reduction 
will continue (due to COVID-19-related concerns) for up 
to 3 months. Emergency presentations are assumed to 
continue at their usual rate. Therefore, we re-allocated 
the backlog of patients in months 4–12 to 2-week-wait 
pathways and emergency presentations. And scenario C 
is the same as scenario B, but we simulated the effect of 
2-week-wait referrals continuing to be reduced beyond 
the first 3-month period by 25% for a further 3-month 
period—ie, until month 6 after introduction of physical 
distancing measures. Under this scenario, emergency 
presentations are assumed to continue at the usual rate. 
Therefore, we re-allocated the backlog of patients in 
months 7–12 to 2-week-wait pathways and emergency 
presentations.
Statistical analysis
We randomly modified the mode of presentation and 
dates of diagnosis of the pre-pandemic cohorts according 
to scenarios A–C. We reallocated patients diagnosed 
through screening and routine referral pathways (out-
patient or inpatient) to either emergency presentation or 
2-week-wait referral routes. For scenarios B and C, we 
reallocated a proportion of patients diagnosed through the 
2-week-wait pathway because under these scenarios this 
referral route was assumed to operate at 20% (scenario B) 
and 75% (scenario C) of its usual capacity.
We estimated the reallocation of patients from routine 
and screening pathways to the emergency presentation 
route at the same proportion observed in the pre-
pandemic cohorts (table 1).
To estimate the impact that the response to the COVID-19 
pandemic could have on cancer survival, we compared the 
net survival of pre-pandemic cohorts of patients with 
cancer to that of patients diagnosed according to the 
postulated scenarios A–C. Notably, for colorectal cancer, 
even though the reallocation from routine to urgent 
pathways was done separately for patients with rectal and 
colon cancer, the survival estimates are for the combined 
colorectal cancer population. We translated the differences 
in net survival between pre-pandemic and pandemic 
cohorts into the number of deaths due to cancer for each 
scenario. Compared with the number of deaths due to 
cancer in the pre-pandemic cohorts, we derived the 
additional number of deaths due to cancer and addi tional 
number of YLLs. We calculated point estimates and 
95% CIs using bootstrap resampling.
We obtained our estimates via multivariable excess 
hazard models. For these population-based data, we 
retrieved the measure of interest (excess mor tality due to 
cancer) by removing the effect of competing risks 
of death (ie, deaths due to causes other than the cancer of 
interest).19 We derived these competing risks from 
general population life tables defined by sex, single years 
of age, calendar years, deprivation quintile, and 
Figure 1: Conceptual framework for reallocation of pre-pandemic referral routes in three modelling scenarios (A, B, and C)
For breast cancer, in addition to patients on routine pathways, only 25% of patients diagnosed through screening (ie, the proportion of patients with tumour stage III 












2-week wait or emergency presentation, both at 100% capacity
2-week wait or emergency presentation, both at 100% capacity









Time since March 16, 2020 (months)Scenario
2-week wait or emergency presentation, both at
100% capacity
2-week wait, 
at 20% capacity 
Emergency presentation, 
at 100% capacity
For life tables used see https://
icon.lshtm.ac.uk/life-tables/
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Patients Stage III–IV* Net survival
1 year 3 years 5 years
Breast cancer
Pre-pandemic period
Emergency presentation 930 (2·9%) 245/356 (68·8%) 56·3% (53·9–58·6) 39·0% (37·0–41·0) 33·4% (31·8–35·1)
GP referral 5136 (15·8%) 566/2836 (20·0%) 96·3% (96·2–96·3) 90·0% (89·9–90·1) 86·2% (86·2–86·3)
Other routine† 887 (2·7%) 93/418 (22·2%) 94·0% (93·8–94·2) 85·8% (85·5–86·1) 81·3% (81·0–81·7)
Screening 10 795 (33·1%) 406/6789 (6·0%) 100·0% (100–100) 99·6% (99·6–99·6) 98·8% (98·8–98·8)
2-week wait 14 835 (45·5%) 1821/8934 (20·4%) 97·9% (97·9–97·9) 91·3% (91·3–91·4) 86·3% (86·2–86·3)
Overall 32 583 (100%) ·· 97·0% (97·0–97·1) 92·2% (92·2–92·3) 88·8% (88·7–88·8)
Pandemic period
Scenario A ·· ·· 96·0% (95·9–96·1) 89·0% (88·9–89·1) 83·9% (83·9–84·0)
Emergency presentation 1149 (4·7%) ·· ·· ·· ··
2-week wait 23 357 (95·3%) ·· ·· ·· ··
Scenario B ·· ·· 95·9% (95·9–96·0) 88·8% (88·7–88·9) 83·6% (83·6–83·7)
Emergency presentation 1225 (5·0%) ·· ·· ·· ··
2-week wait 23 286 (95·0%) ·· ·· ·· ··
Scenario C ·· ·· 95·9% (95·8–96·0) 88·7% (88·6–88·8) 83·6% (83·5–83·6)
Emergency presentation 1249 (5·1%) ·· ·· ·· ··
2-week wait 23 240 (94·9%) ·· ·· ·· ··
Colorectal cancer‡
Pre-pandemic period
Emergency presentation ·· ·· 54·8% (54·6–55·1) 40·3% (40·1–40·4) 35·1% (34·9–35·2)
Colon 4143 (26·1%) 1753/2263 (77·5%) ·· ·· ··
Rectum 1040 (11·4%) 459/584 (78·6%) ·· ·· ··
GP referral ·· ·· 83·5% (83·4–83·5) 70·6% (70·5–70·7) 64·4% (64·3–64·4)
Colon 3769 (23·8%) 1262/2082 (60·6%) ·· ·· ··
Rectum 2538 (27·9%) 903/1531 (59·0%) ·· ·· ··
Other routine† ·· ·· 83·7% (83·6–83·8) 71·3% (71·2–71·4) 65·4% (65·3–65·5)
Colon 2063 (13·0%) 666/1112 (59·9%) ·· ·· ··
Rectum 1001 (11·0%) 365/587 (62·2%) ·· ·· ··
Screening ·· ·· 97·5% (97·5–97·5) 92·9% (92·9–93·0) 89·6% (89·6–89·7)
Colon 1922 (12·1%) 431/985 (43·8%) ·· ·· ··
Rectum 1102 (12·1%) 307/677 (45·3%) ·· ·· ··
2-week wait ·· ·· 85·0% (85·0–85·1) 71·2% (71·2–71·3) 64·2% (64·1–64·2)
Colon 3970 (25·0%) 1493/2444 (61·1%) ·· ·· ··
Rectum 3427 (37·6%) 1449/2344 (61·8%) ·· ·· ··
Overall ·· ·· 79·7% (79·7–79·8) 67·3% (67·2–67·3) 61·4% (61·4–61·5)
Colon 15 867 (100%) ·· ·· ·· ··
Rectum 9108 (100%) ·· ·· ·· ··
Pandemic period ·· ·· ·· ·· ··
Scenario A ·· ·· 76·0% (75·9–76·0) 61·9% (61·8–61·9) 55·3% (55·3–55·3)
Emergency presentation
Colon 6166 (38·9%) ·· ·· ·· ··
Rectum 1570 (17·2%) ·· ·· ·· ··
2-week wait
Colon 9700 (61·1%) ·· ·· ·· ··
Rectum 7538 (82·8%) ·· ·· ·· ··
Scenario B
Emergency presentation ·· ·· 75·7% (75·6–75·7) 61·6% (61·6–61·7) 55·1% (55·1–55·2)
Colon 6384 (40·2%) ·· ·· ·· ··
Rectum 1654 (18·2%) ·· ·· ·· ··
(Table 1 continues on next page)
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Patients Stage III–IV* Net survival
1 year 3 years 5 years
(Continued from previous page)
2-week wait
Colon 9482 (59·8%) ·· ·· ·· ··
Rectum 7454 (81·8%) ·· ·· ·· ··
Scenario C
Emergency presentation ·· ·· 75·5% (75·5–75·6) 61·5% (61·4–61·5) 55·0% (55·0–55·0)
Colon 6456 (40·7%) ·· ·· ·· ··
Rectum 1678 (18·4%) ·· ·· ·· ··
2-week wait
Colon 9410 (59·3%) ·· ·· ·· ··
Rectum 7430 (81·6%) ·· ·· ·· ··
Lung cancer
Pre-pandemic period
Emergency presentation 9636 (32·9%) 7674/8690 (88·3%) 15·9% (15·9–15·9) 6·6% (6·6–6·6) 4·6% (4·6–4·6)
GP referral 6549 (22·3%) 4158/6108 (68·1%) 46·4% (46·4–46·4) 26·1% (26·1–26·1) 19·6% (19·6–19·6)
Other routine† 4003 (13·7%) 2483/3732 (66·5%) 50·3% (50·3–50·4) 29·1% (29·1–29·1) 22·0% (22·0–22·0)
2-week wait 9117 (31·1%) 6806/8917 (76·3%) 48·7% (48·7–48·7) 21·9% (21·9–21·9) 13·6% (13·6–13·6)
Overall 29 305 (100%) ·· 37·6% (37·6–37·6) 18·8% (18·8–18·8) 13·1% (13·1–13·1)
Pandemic period
Scenario A ·· ·· 34·1% (34·0–34·1) 15·1% (15·1–15·1) 9·6% (9·6–9·6)
Emergency presentation 12 802 (43·7%) ·· ·· ·· ··
2-week wait 16 503 (56·3%) ·· ·· ·· ··
Scenario B ·· ·· 33·3% (33·3–33·3) 14·7% (14·7–14·7) 9·4% (9·4–9·4)
Emergency presentation 13 715 (46·8%) ·· ·· ·· ··
2-week wait 15 590 (53·2%) ·· ·· ·· ··
Scenario C ·· ·· 33·1% (33·1–33·1) 14·6% (14·6–14·6) 9·3% (9·3–9·3)
Emergency presentation 13 538 (46·2%) ·· ·· ·· ··
2-week wait 15 767 (53·8%) ·· ·· ·· ··
Oesophageal cancer
Pre-pandemic period
Emergency presentation 1228 (18·2%) 258/283 (91·2%) 20·7% (20·3–21·1) 9·5% (9·4–9·7) 7·9% (7·8–8·1)
GP referral 1410 (20·9%) 215/300 (71·7%) 54·8% (54·6–55·0) 27·3% (27·2–27·4) 21·2% (21·0–21·3)
Other routine† 1303 (19·3%) 196/268 (73·1%) 55·7% (55·6–55·9) 29·7% (29·6–29·9) 23·9% (23·7–24·0)
2-week wait 2803 (41·6%) 629/755 (83·3%) 48·2% (48·1–48·3) 19·1% (19·0–19·2) 13·4% (13·3–13·5)
Overall 6744 (100%) ·· 46·0% (45·9–46·1) 21·1% (21·1–21·2) 16·1% (16·0–16·1)
Pandemic period
Scenario A ·· ·· 41·3% (41·2–41·4) 16·7% (16·7–16·8) 12·0% (12·0–12·1)
Emergency presentation 1690 (25·1%) ·· ·· ·· ··
2-week wait 5054 (74·9%) ·· ·· ·· ··
Scenario B ·· ·· 39·9% (39·7–40·0) 15·8% (15·7–15·8) 11·3% (11·3–11·4)
Emergency presentation 1783 (26·4%) ·· ·· ·· ··
2-week wait 4961 (73·6%) ·· ·· ·· ··
Scenario C ·· ·· 39·7% (39·6–39·8) 15·7% (15·7–15·8) 11·3% (11·2–11·3)
Emergency presentation 1812 (26·9%) ·· ·· ·· ··
2-week wait 4932 (73·1%) ·· ·· ·· ··
Data are n (%), n/N (%), or net survival with 95% CI in parentheses. For breast cancer, in addition to patients on routine pathways, only 25% (n=2700) of patients diagnosed 
through screening (ie, the proportion of patients with T3, T4, node positive, or metastatic disease) were reallocated to 2-week wait and emergency presentation in the 
pandemic scenarios. *The proportion of patients diagnosed with stage III or IV disease is based on patients with available staging information in the cancer registry dataset 
and has been reported to show the stage variation according to diagnostic referral route; information on cancer stage is not used in the modelling of net survival. †Includes 
referrals within secondary care. ‡Net survival for colorectal cancer is for both colon and rectum tumour type combined. However, allocation of patients to 2-week wait and 
emergency presentation diagnostic routes was done separately for each tumour type.
Table 1: Distribution of patients by referral pathway, stage of cancer, and 1-year, 3-year, and 5-year net survival in the pre-pandemic period and by each 
pandemic scenario
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Government Office Regions. All-cause mortality from 
general popu lation life tables includes cancer-related 
mortality. Since each cancer site-specific mortality is a 
negligible cause of death, all-cause mortality, as estimated 
from population life tables, is the mortality that patients 
with cancer would experience, had they not been diag-
nosed with cancer.20,21 Further details and mathe matical 
formulae are in the appendix (pp 1–3). We did all 
statistical analyses using Stata (version 16.1).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. CM, BR, and AA had full access to all the data 
in the study and had final responsibility for the decision 
to submit to publication.
Results
We analysed data on 32 583 patients with breast cancer, 
24 975 with colorectal cancer, 29 305 with lung cancer, 
and 6744 with oesophageal cancer (table 1). Patients were 
all diagnosed in England. Patients were aged 15–84 years 
and the mean age at diagnosis was 60·5 years (SD 12·6) 
for breast cancer, 68·5 years (10·7) for colorectal cancer, 
68·5 years (10·3) for oesophageal cancer, and 69·8 years 
(9·3) for lung cancer. 10 441 (41·8%) of 24 975 patients 
diagnosed with colorectal cancer, 13 211 (45·1%) of 
29 305 diagnosed with lung cancer, and 1894 (28·1%) of 
Number of deaths due to cancer Additional number of deaths due to cancer
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Data are cumulative number of deaths or percentage change in number of deaths, with 95% CIs in parentheses. Point estimates and 95% CIs were calculated from bootstrap samples of the original data.
Table 2: Estimated cumulative number of deaths due to cancer up to 1 year, 3 years, and 5 years after diagnosis, in the pre-pandemic period and for each pandemic scenario A–C 
(also presented as additional number of deaths)
See Online for appendix
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6744 diagnosed with oesophageal cancer were women. In 
the pre-pandemic period, survival varied substantially by 
tumour type and referral pathway, with the worst 
prognosis evident for oesophageal and lung cancers and 
for patients diagnosed after an emergency presentation. 
The proportion of patients diagnosed through emergency 
presentation pathways varied substantially across tumour 
types. These differences in sur vival between referral 
path ways correlated with increased proportions of 
patients diagnosed at stages III and IV, irrespective of 
tumour type (table 1; appendix p 4). Notably, 2-week-wait 
referral pathways are not associated with substantial 
differences in stage or survival compared with non-
urgent referral routes.
We estimated the impact of diagnostic delay for the 
12-month period from March 16, 2020, to March 15, 2021. 
Across scenarios A–C, we estimated an absolute decrease 
in cancer survival ranging between 1·0–1·1% (breast, all 
scenarios) and 6·1–6·3% (oesophageal, scenarios B and C) 
at 1 year after diagnosis, and between 3·5% (lung, 
scenario A) and 6·4% (colorectal, scenario C) at 5 years 
after diagnosis (table 1).
The differences in survival translate into substantial 
additional numbers of deaths due to cancer in the first 
5 years of follow-up. The estimated number of deaths 
due to each cancer up to 1, 3, and 5 years after diagnosis 
in the pre-pandemic period and across scenarios A–C are 
shown in table 2. The number of additional cancer deaths 
estimated across the scenarios are shown as cumulative 
estimates up to year 5 (table 2, figure 2).
We estimated across scenarios A–C, compared with the 
pre-pandemic period, a 2·1–6·6% increase in the number 
of deaths due to breast cancer up to year 1 (corresponding 
to between 20 [95% CI 15–25] and 63 [57–70] additional 
deaths), a 6·8–9·1% increase up to year 3 (169 [159–179] to 
228 [218–239] additional deaths), and a 7·9–9·6% increase 
up to year 5 (281 [266–295] to 344 [329–358] additional 
deaths). For colorectal cancer across scenarios A–C, we 
estimated an 18·2–20·3% increase in deaths due to 
cancer up to year 1 (921 [894–970] to 1027 [999–1094] 
additional deaths), a 16·1–17·6% increase up to year 3 
(1301 [1257–1411] to 1414 [1371–1568] additional deaths), 
and a 15·3–16·6% increase up to year 5 (1445 [1392–1591) 
to 1563 [1534–1592] additional deaths). For lung cancer 
across scenarios A–C, we estimated a 6·0–7·7% increase 
in the number of deaths due to cancer up to year 1 
(1102 [1087–1117] to 1412 [1379–1447] additional deaths), 
a 5·1–5·8% increase up to year 3 (1231 [1216–1249] to 
1412 [1381–1442] additional deaths), and a 4·8–5·3% 
increase up to year 5 (1235 [1220–1254] to 1372 [1343–1401] 
additional deaths). For oesophageal cancer, across 
scenarios A–C, we estimated a 9·3–10·3% increase in 
deaths due to cancer up to year 1 (339 [334–343] to 
377 [372–383] additional deaths), a 6·4–6·7% increase up 
to year 3 (343 [337–348] to 359 [354–365] additional deaths) 
and a 5·8–6·0% increase up to year 5 (330 [324–335] to 
342 [336–348] additional deaths).
The plateau in additional deaths due to cancer over the 
5-year period for lung and oesophageal cancer (figure 2) 
reflects relatively higher proportions of early cancer 
deaths at year 1 due to more advanced stage at presen-
tation in our scenarios. In the pre-pandemic period, 
some of these patients would have been expected to die 
Figure 2: Estimated additional number of cancer deaths for each pandemic scenario A–C, for breast cancer (A), 
colorectal cancer (B), lung cancer (C), and oesophageal cancer (D)
















0 1 2 3 4 5
A BBreast Colorectal
0 1 2 3






















Years of life lost (95% CI)
Breast cancer (n=32 583)
Scenario A 8181 (7797–8535)
Scenario B 9033 (8638–9390)
Scenario C 9261 (8843–9631)
Colorectal cancer (n=24 975)
Scenario A 27 735 (27 188–28 241)
Scenario B 25 583 (24 792–27 744)
Scenario C 27 043 (26 234–29 968)
Lung cancer (n=29 305)
Scenario A 20 537 (20 184–20 947)
Scenario B 20 860 (20 250–21 277)
Scenario C 20 413 (19 833–20 909)
Oesophageal cancer (n=6744)
Scenario A 5373 (5227–5530)
Scenario B 5152 (5006–5301)
Scenario C 5027 (4861–5213)
Point estimates and 95% CIs were calculated from bootstrap samples of the 
original data.
Table 3: Estimated years of life lost from additional deaths due to cancer, 
at 5 years from diagnosis, for each pandemic scenario
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beyond year 1 as a result of less advanced disease at 
presentation compared with the pandemic scenarios.
Overall, in comparison with the pre-pandemic period, 
the estimated number of additional deaths attributable to 
these four cancers at 5 years is between 3291 and 3621 deaths 
across the scenarios due to delays in cancer diagnosis 
(table 2, figure 2). These additional cancer deaths in the 
first few years after diagnosis translate into expected YLLs 
in the entire cohort of patients. At 5 years, across 
scenarios A–C, the total additional YLLs for each cancer 
type is shown in table 3. Colorectal cancer and lung cancer 
are associated with the largest number of YLLs due to 
delays in the diagnostic pathways. We estimated the 
expected YLLs to be between 59 204 and 63 229 years 
because of additional deaths due to these four cancers in 
the first 5 years after diagnosis.
Discussion
We estimated that across the four major tumour 
types, breast, colorectal, lung, and oesophageal, 3291 to 
3621 avoid able deaths and an additional 59 204 to 
63 229 YLLs will be attributable to delays in cancer 
diagnosis alone as a result of the COVID-19 lockdown in 
the UK. The increase in deaths due to cancer up to 
5 years after diagnosis ranged from 4·8% for lung cancer 
to 16·6% for colorectal cancer. These additional deaths 
are projected to occur as a conse quence of the national 
COVID-19 pandemic measures, which have reduced the 
number of people seeking health care and access to and 
availability of diagnostic services. Our findings com-
plement those from a study by Sud and colleagues22 
showing the impact of treatment delay, predominantly 
surgical, on excess mortality.
From the onset of the lockdown, essential diagnostic 
services (eg, endoscopy) were suspended or operating at 
substantially reduced capacity, even through the urgent 
2-week-wait referral pathway. The number of endo scopies 
done in April, 2020, was 90% fewer than the number done 
in each of the first three months of 2020.23 As of June, 
2020, these diagnostic services had restarted but at reduced 
capacities.24 These suspensions were due to the perceived 
risk of exposure to SARS-CoV-2 for patients and clinicians, 
and because of re-deployment of staff towards critical care 
to manage patients with COVID-19. This combination of 
perceived risk and redeployment of staff will result in 
further delays, which could also affect survival, that are not 
included in our model. Our results also highlight the 
substantial proportion of patients diag nosed with cancer 
through routine outpatient referral pathways (30–40%) 
and the subsequent effect of deferral and delay in these 
referral pathways during the pandemic. Even when routine 
diagnostic services are re-initiated, substantial delays in 
routine and 2-week-wait referral pathways are to be 
expected due to backlogs currently building up across all 
benign and malignant medical and surgical subspecialities.
Changes in health-seeking behaviour have meant that 
routine referrals from GPs have reduced in volume 
because patients are being asked to only present if they 
have major or urgent concerns.12 Additionally, whether 
the increasing number of remote consultations via tele-
phone or videoconferencing will result in an increased 
proportion of missed diagnoses, without the ability to 
examine and triage the patient directly, is unknown.
Conversely, increased diagnostic efficiency has poten-
tially been introduced into the system as a result of 
the pandemic. For example, patients who now report 
a symptom to their GP are an enriched population com-
pared with those who reported in the pre-pandemic 
period and are potentially more likely to have cancer. 
Simi larly, selection by GPs of patients for further 
investigation is likely to yield an increased proportion of 
cancer diagnoses. However, these effects are likely to be 
small when considering concerns about the overall 
shortfall in the number of new cancer diagnoses. Addi-
tionally, as of June 18, 2020, 2-week-wait referrals are still 
not operat ing at their usual pre-pandemic level, 
particularly for endoscopic intervention.25
Our findings reflect the urgent need for policy inter-
ventions to mitigate the predicted additional cancer deaths 
resulting from delays in diagnosis. Key areas to consider 
include public health messaging, the public’s perception of 
their personal risk of severe illness from COVID-19 versus 
the risks of not seeking health-care advice if they are 
experiencing symptoms suggestive of cancer, provision of 
evidence-based information to enable health-care workers 
to adequately manage the risks for patients with suspected 
cancer during the pandemic with respect to the balance of 
risks and benefits of procedures, and to consider options 
and opportunities for increasing diagnostic capacity.
In the UK, the Stay at Home and subsequent Stay Alert 
public health messaging has had a substantial effect on 
health-seeking behaviour.26 Even as lockdown measures 
are being relaxed, presentation to primary care services 
continues to be much lower than pre-pandemic levels,25 
and we cannot assume that, once all restrictions have 
been lifted, presentations will return to pre-pandemic 
levels in the next 3–6 months. Any exit strategy from 
lockdown27 therefore needs to include accurate and 
measured public health messaging that is tailored 
towards patients, GPs, and secondary care services that 
puts into perspective the risk of death from COVID-19 
compared with other serious illnesses. Dedicated cancer 
awareness programmes will need to consider a range of 
media channels to reach their target groups, including 
direct messaging from GPs to their patients to seek 
attention if they are having new or worrying symptoms.
Increasing diagnostic capacity is complex because it 
necessitates effective coordination across all hospital 
subspecialities and not just in specialist cancer teams. 
Additionally, the requirement for full personal protective 
equipment when doing procedures and the initiation of 
robust cleaning protocols between patients has reduced 
capacity compared with pre-pandemic levels. In the 
short term, diagnostic capacity can be increased through 
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changes in working patterns—eg, increased working 
hours and 7 days-a-week working. Furthermore, a central 
coordinating system for diagnostic investigations in a 
similar vein to a choose-and-book approach, whereby 
primary care physicians are able to refer patients to any 
NHS hospital, will optimise use of capacity.28 For 
detection of bowel cancer, surgeons are increasingly 
using new tools such as the faecal immuno chemical 
test29 to triage their patients for investigation to avoid 
unnecessary colonoscopy and CT imaging and therefore 
improving capacity in this diagnostic pathway.
The paucity of information for health-care workers and 
patients regarding their risk of contracting COVID-19 
from different health-care interactions remains a chal-
lenge as hospitals plan for restarting routine services. 
Antibody testing would increase confidence in clinicians 
doing procedures if immunity to SARS-CoV-2 does exist 
for even a short period.30 The health-care community 
needs accurate data on the true nosocomial risk of 
COVID-19 depending on the type of diagnostic procedure 
being done—eg, colonoscopy versus CT scan. When 
rapid antigen testing becomes routinely available, 
patients requiring investigation can receive testing on 
the day of the procedure and their risks can be managed 
accordingly. Equally, the implication of contracting 
COVID-19 needs to be considered—specifically, to be 
able to counsel patients effectively on the true risk of life-
threatening illness and death.
A strength of this study is the use of linked national 
administrative health records of actual patients diagnosed 
and treated in the NHS for the four tumour types. These 
records provide a robust template for understanding the 
impact of current and predicted changes in availability, 
access, and health-seeking behaviour in response to the 
COVID-19 pandemic on cancer survival. This method 
does not require any de-novo estimation of changes in 
cancer outcomes but derives this estimation from 
previous real-world observations.
We chose the routes-to-diagnosis concept as our method 
to analyse diagnostic delay to overcome some of the 
challenges that have been raised in the scientific literature 
regarding the relative risk of death from diagnostic delay 
across tumours.2,31,32 Inconsistencies in the evidence are 
primarily associated with flaws in study design in which 
the true onset of symptoms remains unclear. Additionally, 
recent work has pointed to a waiting time paradox, 
whereby quicker diagnosis is associated with later stage of 
presentation; this paradox confounds assessment of the 
impact of diagnostic delay on outcomes.33,34 Modelling the 
extent and duration of diagnostic delay at the popula-
tion level is challenging because diagnostic delays are 
predicated on health system factors, such as access and 
availability of diagnostic capacity, and patient-level factors 
(awareness, symptoms, health-seeking behaviour). Our 
model accounts for both of these factors and is grounded 
in the reality of current service levels in the English 
NHS by providing best and worst case estimates. We 
acknowledge that our approach might underestimate or 
overestimate the impact of diagnostic delay on survival, 
and retrospective evaluation will be necessary to further 
appraise this modelling approach.
Our model assumes that disruptions due to the 
COVID-19 pandemic will affect timely access to routine 
and urgent diagnostic services and alter health-seeking 
behaviour for a 12-month period. These assumptions are 
likely given the changes in patterns of patient presentation 
and availability of diagnostic services observed since the 
start of lockdown.1,11,12,24,25 Since beginning our modelling 
study, substantial reduction in 2-week-wait referrals have 
indeed been seen in the first 3 months, as we predicted in 
scenarios B and C. Scenario A conservatively considers no 
reduction in 2-week-wait referrals. Given the ongoing 
reductions in the volume of 2-week-wait referrals (estim-
ates suggest a 40–50% reduction),35 reductions are expected 
to continue for up to 6 months as predicted in scenario C 
because of the effects of pandemic lockdown measures on 
patients presenting to their GP or health-care provider. 
These measures include advice to minimise non-essential 
travel and the continued shielding of high-risk groups.1,12 
Cancer Research UK has estimated that the first 10 weeks 
of the UK lockdown has already resulted in 2·1 million 
deferred cancer screening investigations with 290 000 fewer 
people being referred on 2-week-wait pathways.35 
6 months after the implementation of physical 
distancing mea sures the backlog of patients with potential 
cancers awaiting investigation will be considerable, and 
health-care presentations will continue to be affected due 
to physical distancing measures that are expected to 
continue until 2021.11,12 Additionally, NHS hospital trusts 
suspended their routine diagnostic services at the start of 
lockdown, which is concerning because routine referral 
routes account for 30–40% of cancer diagnoses and the 
backlog in this pathway once routine services restart will 
include all patients still awaiting diagnostic investigations 
both from before and after lockdown started. Further 
competition for capacity will subsequently come from the 
increase in new referrals for suspected cancers on 2-week-
wait referrals and those referred for investigation or follow 
up of seemingly benign health conditions. At the same 
time, diagnostic capacity has decreased for some proce-
dures due the increased time taken per case since the 
introduction of new infection control measures.36 
Together, all these factors will increase the likelihood 
of patients becoming symptomatic and presenting via 
2-week-wait referral or emergency pathways. Alternatively, 
if or when patients are diagnosed through routine 
pathways, the likelihood of stage migration and associated 
worse prognosis due to delays in diagnosis is increased.
Our analysis used a retrospective population cohort, 
therefore, the predicted survival for patients as of 2020 
presenting via the different referral pathways, even for 
patients with stage IV disease, has slightly improved37 in 
the past decade because of improvements in treatments 
and processes of care. However, our analysis focuses on 
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the differences in cancer deaths between two situations 
(pre-pandemic and pandemic periods) and not on the 
absolute numbers of cancer deaths. Additionally, these 
estimates do not consider the impact of treatment delay 
or suboptimal treatment on survival during the 
pandemic.22 The proportions of patients presenting 
through different referral pathways has changed over 
time, with decreasing proportions of patients presenting 
via emergency depart ments in the past decade, which 
might also affect our results.38 However, we consider the 
probable effect on the overall results to be small given the 
steady trajectories of improvements in patterns of 
presentation we have seen over the past 5 years.37,38
We did not analyse patients aged 85 years or older at 
diagnosis because competing events, such as deaths 
from other causes, are predominant in this population. 
Although delays in cancer diagnosis in older populations 
will lead to excess short-term cancer mortality, the effect 
on national population-levels is less likely to be affected. 
Furthermore, because we report survival up to 5 years 
after diagnosis, such an estimate is less reliable in 
patients aged 90 years and older.
In the screening population, we recognise that not all 
patients diagnosed with breast cancer through this route 
would have progressed or developed symptomatic disease. 
As a result, we included only 25% of this cohort in our 
reallocation. For colorectal cancer, 10% of patients are 
diagnosed through the screening route, of whom 45% are 
diagnosed with stage III–IV disease (70% stage II–IV) 
compared with 6% diagnosed with stage III–IV tumours 
through breast cancer screening; hence, we showed that 
more patients with colorectal cancer are diagnosed with 
advanced disease at screening compared with those 
diagnosed with breast cancer. Overdiagnosis and over-
treatment are not specific concerns associated with the 
bowel screening programme,39 whereas they are concerns 
associated with breast screening, and the suspension of 
the bowel screening programme is likely to result in 
delayed presentation and stage migration if cancers 
remain untreated.40
Our model also considered the English NHS as a 
whole, and therefore assigned blanket reallocation across 
the country. However, we recognise that variation is 
probable across the country in terms of GP access, the 
burden of COVID-19, and the extent of discontinuation 
of critical diagnostic services in secondary care settings. 
In this regard, we acknowledge that 2-week-wait referrals 
have not decreased uniformly by 80% across all tumour 
types and UK regions, as per our estimations in 
scenarios B and C. Additionally, variation will exist in 
the recovery of services across regions and individual 
hospitals, which are not included in our estimations.
In summary, we estimated that changes in health-
seeking behaviour and the availability of and access to 
essential diagnostic services resulting from national 
pandemic measures will result in a large number of 
additional deaths from breast, colorectal, lung, and 
oesophageal cancer in the medium (1 year) and longer 
term (5 years). Our study results do not consider the 
effect of delay on other cancer types, or the additional 
effect of changes in treatment pathways for these cancers 
that are likely to substantially increase the expected 
avoidable deaths beyond what we have estimated. Urgent 
policy interventions are necessary to mitigate the indirect 
effects of the COVID-19 pandemic on patients with 
cancer. These interventions should focus on increasing 
routine diagnostic capacity through which up to 40% of 
patients with cancer are diagnosed, public health mes-
saging that accurately conveys the risk of severe illness 
from COVID-19 versus the risks of not seeking health-
care advice if patients are symptomatic, and the provision 
of evidence-based information for clinicians to adequately 
manage the risks of patients to the risk and benefits of 
procedures during the pandemic.
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